Originally published In Press as doi:10.1074/jbc.M105607200 on September 10, 2001
J. Biol. Chem., Vol. 276, Issue 45, 41841-41849, November 9, 2001
Definition of a Dioxin Receptor Mutant That Is a Constitutive
Activator of Transcription
DELINEATION OF OVERLAPPING REPRESSION AND LIGAND BINDING
FUNCTIONS WITHIN THE PAS DOMAIN*
Jacqueline
McGuire
,
Kensaku
Okamoto
,
Murray L.
Whitelaw§,
Hirotoshi
Tanaka¶, and
Lorenz
Poellinger
From the
Department of Cell and Molecular Biology,
Medical Nobel Institute, Karolinska Institute, S-171 77 Stockholm,
Sweden, the § Department of Biochemistry, University of
Adelaide, Adelaide, South Australia 5005, Australia, and the
¶ Division of Clinical Immunology, Advanced Clinical Research
Center, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
Received for publication, June 18, 2001, and in revised form, September 6, 2001
 |
ABSTRACT |
The intracellular dioxin (aryl hydrocarbon)
receptor is a ligand-activated transcription factor that mediates the
adaptive and toxic responses to environmental pollutants such as
2,3,7,8-tetrachlorodibenzo-p-dioxin and structurally
related congeners. Whereas the ligand-free receptor is characterized by
its association with the molecular chaperone hsp90, exposure to ligand
initiates a multistep activation process involving nuclear
translocation, dissociation from the hsp90 complex, and dimerization
with its partner protein Arnt. In this study, we have characterized a
dioxin receptor deletion mutant lacking the minimal ligand-binding
domain of the receptor. This mutant did not bind ligand and localized
constitutively to the nucleus. However, this protein was functionally
inert since it failed to dimerize with Arnt and to bind DNA. In
contrast, a dioxin receptor deletion mutant lacking the minimal PAS B
motif but maintaining the N-terminal half of the ligand-binding domain
showed constitutive dimerization with Arnt, bound DNA, and activated
transcription in a ligand-independent manner. Interestingly, this
mutant showed a more potent functional activity than the
dioxin-activated wild-type receptor in several different cell lines. In
conclusion, the constitutively active dioxin receptor may provide an
important mechanistic tool to investigate receptor-mediated regulatory
pathways in closer detail.
 |
INTRODUCTION |
The intracellular dioxin receptor also known as the aryl
hydrocarbon receptor, is a ligand-dependent transcription
factor that mediates the biological effects of
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD),1 commonly known as
dioxin (1). Although disruption of the dioxin receptor gene in mice has
not yielded conclusive results, it remains a possible scenario that
physiological mechanisms may exist for activation of receptor function,
e.g. during critical stages of vertebrate development
(2-5). However, an endogenous ligand for the receptor has not yet been
identified, suggesting that alternative pathways for receptor
activation may exist.
In the absence of ligand, the dioxin receptor is generally found in the
cytoplasm associated in high molecular weight complexes comprising a
dimer of the molecular chaperone hsp90, an immunophilin homolog known
as XAP2 (hepatitis B virus X-associated
protein-2)/AIP (aryl hydrocarbon
receptor-interacting protein)/ARA9
(aryl hydrocarbon receptor-associated protein-9), and
the co-chaperone p23 (6-11). In the presence of dioxin, the receptor
is converted to a functional DNA-binding species in a multistep process
involving nuclear translocation, dissociation from the hsp90 complex,
and dimerization with its partner protein Arnt (Ah
receptor nuclear translocator).
Formation of the dioxin receptor/Arnt heterodimer is a prerequisite for DNA binding and promotes transcription of target genes including those
encoding xenobiotic-metabolizing enzymes such as CYP1A1 (1). Both the dioxin receptor and Arnt are members of a distinct subclass of the basic helix-loop-helix (bHLH) family of transcriptional regulators known as bHLH/PAS proteins. Members of this potent subfamily
mediate diverse biological processes, including response to hypoxia,
circadian rhythmicity, and development of the central nervous
system (1, 12, 13). Contiguous to the amino-terminal bHLH DNA-binding
and dimerization motifs, members of this subfamily are identified on
the basis of a second region of homology, the PAS
(Per-Arnt-Sim) domain, originally
identified in the Drosophila proteins PER and SIM,
and Arnt. The PAS domain encompasses a region of ~250-300 amino
acids harboring two degenerate repeat sequences of 44 amino acids
termed PAS A and PAS B, respectively, and has been shown to constitute
an additional dimerization interface that can function independently of
the bHLH motif (14, 15). More recently, additional roles in the
regulation of heterodimerization and DNA binding specificities have
been attributed to the PAS domain (16, 17). In the case of the dioxin
receptor, the carboxyl-terminal half of the PAS domain, spanning the
hydrophobic PAS B repeat motif, has been shown to harbor the core
ligand-binding activity of the receptor (18, 19). In addition to
binding ligand, this region has also been shown to mediate association
with the molecular chaperone hsp90 (19), consistent with a role for
hsp90 in regulating signal responsiveness by folding the ligand-binding
domain (LBD) into a high affinity ligand binding conformation (20-22).
Taken together, the PAS domain appears to be a complex structure
harboring a number of distinct functional activities.
In our efforts to understand further the complex interplay between
structure and function of the dioxin receptor, we have examined the
functional activity of a dioxin receptor deletion mutant lacking the
core LBD. Although this protein is constitutively localized to the
nucleus, it was functionally inert on a xenobiotic response element
(XRE)-driven reporter gene both in the presence and absence of ligand.
In contrast, deletion of amino acids 288-421 encompassing the minimal
PAS B motif generated an activated form of the receptor that stimulated
transcription in the absence of ligand, demonstrating that this mutant
functions as a constitutively active regulatory protein. Interestingly,
this mutant showed a more potent functional activity than the
dioxin-activated wild-type receptor, possibly indicating that exposure
to ligand does not induce maximal activation of the receptor.
 |
EXPERIMENTAL PROCEDURES |
Plasmid Constructions--
The plasmids used for in
vitro translation of the full-length dioxin receptor
(mDR/ATG/pSP72) and Arnt (Arnt/pGem) have been described
previously (23, 24). For construction of the dioxin receptor deletion
mutants DR
LBD and DR
PASB, pSportAhR containing full-length murine
dioxin receptor cDNA (18) was amplified by PCR using primers
designed to yield fragments of the dioxin receptor encoding codons
1-229 and 1-287, respectively. Primers were designed to carry
restriction sites for ClaI and XhoI, enabling
directional insertion into ClaI/XhoI-digested
pGem7 to give pDR1-229/Gem and pDR1-287/Gem, respectively. A dioxin
receptor fragment encompassing codons 422-805 was obtained by PCR from
pSportAhR using specific primers carrying restriction sites for
XhoI. The resulting fragment was digested with
XhoI and subcloned into XhoI-digested
pDR1-229/Gem and pDR1-287/Gem to give pDR
LBD/Gem and
pDR
PASB/Gem, respectively. Whenever possible, PCR sequence was
replaced by natural dioxin receptor sequences from mDR/ATG/pSP72 (23).
All constructs were confirmed by DNA sequence analysis.
ClaI/XbaI digestion of the corresponding pDR/Gem
constructs followed by subcloning into
ClaI/XbaI-digested eukaryotic expression plasmid
pCMV4 yielded constructs pDR
LBD/CMV4 and pDR
PASB/CMV4. The
FLAG-tagged expression constructs pDR-FLAG/CMV4 and
pDR
PASB-FLAG/CMV4 were constructed by incorporating a FLAG tag
epitope (Sigma), produced by PCR, at the extreme 3'-end of the coding
sequence of the respective cDNAs. The pCMX-SAH/Y145F expression
vector, encoding a modified and highly chromophoric form of green
fluorescent protein (GFP) under the control of the cytomegalovirus
promoter, has been described previously (25). To create a GFP fusion
construct of the full-length dioxin receptor for expression and
visualization in living cells, a PCR fragment was amplified from
pSportAhR using primers designed to yield a fragment of the dioxin
receptor encoding codons 1-287. Primers were designed to carry
restriction sites for BamHI and NheI, enabling in-frame directional insertion into
BamHI/NheI-digested pCMX-SAH/Y145F. A
CelII/XbaI dioxin receptor fragment
encompassing amino acids 72-805 isolated from mDR/ATG/pSP72 was then
inserted to provide the final construct pGFP-mDR/CMX. GFP fusion
constructs for DR
LBD and DR
PASB were produced by digesting
pGFP-mDR/CMX with CelII/NotI and replacing with
CelII/NotI fragments isolated from pDR
LBD/Gem and pDR
PASB/Gem, thereby producing pGFP-DR
LBD/CMX and
pGFP-DR
PASB/CMX, respectively. To produce the GFP fusion construct
containing the minimal LBD of the dioxin receptor, a PCR fragment
encoding codons 230-421 was amplified from pSportAhR. The primers were
designed to carry restriction sites for XhoI, enabling
insertion into SalI-digested pCMX-SAH/Y145F to give
pGFP-DRLBD/CMX. pGRDBD/CMV4 and pGRDBDmDR/CMV4 (previously referred to
as pGRDBDmDR83-805/CMV4) have been described (26). To construct the
glucocorticoid receptor/mouse dioxin receptor deletion constructs for
expression in mammalian cells, a ClaI/XbaI
fragment was isolated from pDR
LBD/Gem and pDR
PASB/Gem and
subcloned into ClaI/XbaI-digested pGRDBD/CMV4 to
give pGRDBD/DR
LBD/CMV4 and pGRDBD/DR
PASB/CMV4, respectively. The
yeast expression vectors pGRDBD/2HG and pGRDBDmDR/2HG (previously
referred to as pGRDBDmDR83-805/2HG) have been described (22). To
construct the glucocorticoid receptor/mouse dioxin receptor deletion
constructs for expression in yeast, an NcoI fragment was
isolated from pDR
LBD/Gem and pDR
PASB/Gem and subcloned into
NcoI-digested pGRDBDmDR/2HG to give pGRDBD/DR
LBD/2HG and
pGRDBD/DR
PASB/2HG, respectively. The mammalian reporter gene constructs pTX.DIR and p(GRE)2T105LUC and the yeast
reporter plasmid pUC
SS26X have been described previously
(27-29).
Cell Culture and Transient Transfection Assays--
CHO cells
were grown in Ham's F-12 medium, and HeLa cells were grown in
Dulbecco's modified Eagle's medium supplemented with 2 mM
L-glutamine, 10% fetal calf serum, 100 IU of penicillin, and 100 mg/ml streptomycin (Life Technologies, Inc.). For reporter gene
assays, cells were transiently transfected with 2 µg of reporter plasmid and 1 µg of expression plasmids using LipofectAMINE (Life Technologies, Inc.) according to the manufacturer's recommendations. After a 6-h transfection period, cells were induced either with 10 nM TCDD (Cambridge Isotope Laboratories) or with an
equivalent volume of vehicle (Me2SO) alone. Following
incubation for 48 h, cells were collected and washed with PBS;
extracts were prepared; and luciferase activity was measured.
Experiments were carried out in duplicate, and extracts were normalized
for protein concentration. For immunoblot analysis, transfected CHO
cells were collected, washed with PBS, and lysed in 50 µl of whole
cell extract buffer (20 mM Hepes, pH 7.9, 1.5 mM MgSO4, 0.2 mM EDTA, 0.42 M NaCl, 0.5% (v/v) Nonidet P-40, 25% (v/v) glycerol, 1 mM dithiothreitol, and 1 mM
phenylmethylsulfonyl fluoride) on ice for 30 min. Following centrifugation, the resulting supernatants were used as whole cell
extracts. Samples containing 30 µg of protein were separated by
SDS-polyacrylamide gel electrophoresis (PAGE) and electroblotted onto
nitrocellulose membranes. Immunodetection was achieved by incubation
with mouse monoclonal anti-FLAG antibodies (Sigma), followed by
chemiluminescence using the ECL detection system (Amersham Pharmacia
Biotech).
Yeast Strains, Transformations, and
-Galactosidase
Assays--
The yeast strain GRS4 has been described previously (29).
Transformation of GRS4 with expression plasmids for the indicated glucocorticoid receptor/dioxin receptor fusion proteins together with
the reporter plasmid pUC
SS26X was carried out using a modification of the lithium acetate method (30). Quantitation of
-galactosidase reporter gene activity in GRS4 transformants was carried out as described previously (22).
Subcellular Localization Assay Using GFP Fusion
Proteins--
CHO cells were grown on poly-D-lysine-coated
sterile coverslips in 35-mm diameter dishes and transiently transfected
with 1 µg of each expression plasmid for GFP fusion proteins using 2 µl of FuGENE 6 transfection reagent (Roche Molecular Biochemicals) per dish. After a 6-h incubation, the medium was replaced with fresh
medium, and incubation was continued for a further 24 h. The cells
were then treated with 10 nM TCDD or vehicle
(Me2SO) for 2 h, washed twice with PBS, and fixed with
4% paraformaldehyde in PBS for 15 min at room temperature. After three
washes with PBS, the cells were quickly rinsed with deionized water and
mounted on glass slides using Gel/Mount (Biomeda Co. Ltd.). Subcellular localization of GFP fusion proteins was observed with a Leica DMRXA
fluorescent microscope using the GFP filter set, and images were
scanned with a Hamamatsu digital camera, processed with OpenLab Version
3.0 software, and exported as composite PICT files. For each construct
and each condition, ~200 cells expressing GFP fusion proteins were
observed, and representative images are presented. At least three
independent experiments were carried out for each GFP fusion protein construct.
In Vitro Translation and Co-immunoprecipitation
Experiments--
The wild-type dioxin receptor, the dioxin receptor
deletion constructs DR
LBD and DR
PASB, and Arnt were translated
in vitro in the presence or absence of
[35S]methionine (Amersham Pharmacia Biotech) in rabbit
reticulocyte lysate (Promega) according to the manufacturer's
recommendations. For Arnt co-immunoprecipitation experiments, equal
concentrations of the indicated in vitro translated,
[35S]methionine-labeled proteins were incubated with
in vitro translated, unlabeled Arnt (5 µl) in TEG buffer
(20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 10% (w/v)
glycerol, and 1 mM dithiothreitol) containing CompleteTM mini protease inhibitors (Roche Molecular
Biochemicals) in the presence or absence of 10 nM TCDD
(dioxin) either for 2 h at 25 °C or overnight at 4 °C in a
final volume of 10 µl. Protein mixtures were then precleared by
incubation on ice with 10 µl of preimmune serum for 15 min, followed
by an additional 15-min incubation with 50 µl of a 50% slurry of
protein A-Sepharose in TEG buffer supplemented with 150 mM
NaCl, 0.2% Triton X-100, and 2 mg/ml bovine serum albumin. Following
rapid centrifugation, the resulting supernatants were incubated with 10 µl of either anti-Arnt antiserum (24) or preimmune serum for 1 h
at room temperature. Protein A-Sepharose was then added (50 µl of a
50% slurry in supplemented TEG buffer), and the samples were incubated
on ice for a further 45 min. After brief centrifugation, Sepharose
pellets were washed three times with 500 µl of supplemented TEG
buffer, followed by a final wash with TEG buffer alone.
Co-immunoprecipitated proteins were eluted by boiling in SDS sample
buffer and analyzed by SDS-PAGE and chemiluminescence.
DNA Binding Assay--
DNA binding experiments were performed
with in vitro translated, unlabeled Arnt together with the
wild-type dioxin receptor or the dioxin receptor deletion mutants
DR
LBD and DR
PASB as described previously (31). Briefly,
equivalent concentrations of the indicated in vitro
translated proteins were incubated with 10 µl of in vitro
translated Arnt in the presence or absence of 10 nM TCDD
for 2 h at 25 °C. DNA binding reactions were carried out by the
addition of a 36-base pair 32P-labeled double-stranded
oligonucleotide spanning the XRE1 motif of the rat CYP1A1
promoter (32) in 10 mM Hepes, 5% (v/v) glycerol, 0.05 mM dithiothreitol, 2.5 mM MgCl2, 1 mM EDTA, and 0.08% (w/v) Ficoll in a final volume of 40 µl containing 50 mM NaCl and 1 µg of poly(dI-dC)
nonspecific competitor DNA (Amersham Pharmacia Biotech).
Following incubation for 20 min at 25 °C, protein-DNA complexes were
separated on a 4% low ionic strength native polyacrylamide gel (29:1
acrylamide/bisacrylamide) in Tris/glycine/EDTA buffer at 30 mA
and analyzed by autoradiography.
Ligand Binding Assays--
Ligand binding assays were carried
out essentially as described previously using a modified
hydroxylapatite adsorption assay (21, 23). Briefly, equal
concentrations of the in vitro translated, unlabeled
wild-type dioxin receptor or the indicated dioxin receptor deletion
mutants were made up to a final volume of 10 µl with blank
reticulocyte lysate translation mixture, followed by dilution with 3 volumes of TEG buffer containing 2 mM dithiothreitol, 5 µg/ml protease inhibitor mixture (aprotinin, leupeptin, and
pepstatin A), and 1 mM phenylmethylsulfonyl fluoride. The
reaction mixtures were then incubated with 1 nM
[3H]TCDD (40 Ci/mmol; Chemsyn, Lenexa, KS) in the
presence or absence of a 150-fold molar excess of the specific
competitor tetrachlorodibenzofuran at room temperature for 90 min.
Following incubation, the reaction mixtures were treated with 50 µl
of a 10% slurry (v/v) of dextran-coated charcoal in TEG buffer for 5 min on ice, followed by centrifugation. The resulting supernatants were
then incubated with 50 µl of a 50% slurry (v/v) of hydroxylapatite
in TEG buffer on ice for 30 min. Following rapid centrifugation, the
supernatants were discarded, and the remaining pellets were washed four
times with 500 µl of ice-cold TEG buffer containing 0.1% Tween 20. The pellets were eluted by incubating twice with 500 µl of ethanol,
and the pooled supernatants were analyzed by scintillation counting.
 |
RESULTS |
A Dioxin Receptor Deletion Mutant Lacking the Minimal LBD Is
Constitutively Localized to the Nucleus, but Is Functionally
Inert--
In the absence of ligand, the dioxin receptor exists in the
cytoplasm in a latent, non-DNA-binding form characterized by
association with the heat shock protein hsp90. Exposure to ligand
results in rapid nuclear accumulation of the receptor and conversion to a heterodimeric complex with Arnt, a form that is now competent to bind
DNA and to initiate the transcription of target genes (1). Thus, the
initial step in the activation of dioxin receptor function is binding
of ligand. In addition to being a critical determinant of
ligand-binding activity, the LBD of the dioxin receptor has also been
postulated to be involved in the repression of a number of receptor
activities that map outside the LBD itself such as dimerization with
Arnt, DNA binding, and transcriptional activity (19, 26, 33). It has
not yet been determined how the ligand-binding domain modulates this
repressive activity. However, since hsp90 binding has been shown to
colocalize within this region, it has been suggested that hsp90 itself
may function as the agent of repression either by steric interference
or by misfolding of adjacent structures (19, 22). We were interested to
determine whether deletion of the minimal region of the dioxin receptor
harboring the ligand- and hsp90-binding activities of the receptor
would result in a protein that was uncoupled from regulation by dioxin.
To this end, we have examined the functional activities, both in
vitro and in vivo, of a dioxin receptor deletion mutant
(DR
LBD) lacking the core-delineated LBD that is located between
amino acids 230 and 421 (19, 21) and that spans the C-terminal half of
the PAS domain of the mouse dioxin receptor (Fig.
1A). In control experiments,
in vitro translation of DR
LBD in rabbit reticulocyte
lysate resulted in a protein that had lost the ability to bind ligand,
consistent with deletion of the minimal domain required for high
affinity ligand binding of the dioxin receptor (data not shown).
Furthermore, in a specific co-immunoprecipitation assay using
monoclonal anti-hsp90 antibodies, this protein showed only low levels
of interaction with hsp90 (data not shown) that were attributed to
non-LBD interactions via the bHLH motif (31).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 1.
A dioxin receptor deletion mutant lacking the
minimal LBD is constitutively localized to the nucleus, but is
functionally inert on an XRE-driven reporter gene in CHO cells.
A, shown is schematic representation of the structural
motifs within the full-length mouse dioxin receptor (mDR)
and the dioxin receptor deletion mutant DR LBD. B, shown
is the subcellular distribution of GFP-dioxin receptor fusion proteins.
CHO cells grown on glass coverslips were transiently transfected with 1 µg of each expression plasmid for the indicated dioxin receptor
mutants fused to GFP. Twenty-four hours after transfection, the cells
were treated with 10 nM TCDD or vehicle alone (0.1%
Me2SO) for 2 h as indicated. Cells were then washed
with PBS and fixed with 4% paraformaldehyde as described under
"Experimental Procedures." Subcellular localization of the
expressed GFP fusion proteins was observed using a Leica DMRXA
fluorescent microscope with a GFP filter set. Approximately 200 cells
were observed, and representative images are shown. The experiments
were repeated at least three times for each GFP fusion construct with
similar results. Original magnification was ×400. C, CHO
cells were transiently transfected with the XRE-driven luciferase
reporter gene pTX.DIR together with either the wild-type dioxin
receptor or the dioxin receptor deletion mutant DR LBD and Arnt.
Following transfection, cells were treated with either 10 nM TCDD (black bars) or vehicle alone (0.1%
Me2SO; shaded bars). The control lanes
(CTRL) represent activity from the reporter alone and empty
expression vector. Data are from one experiment performed in duplicate
and are representative of three independent experiments.
|
|
A bipartite nuclear localization signal (NLS) has been identified in
the N terminus of the dioxin receptor, incorporating basic residues
within the DNA-binding domain of the bHLH motif. This single N-terminal
NLS motif has been shown to be sufficient to mediate ligand-inducible
nuclear import of the dioxin receptor in the context of the full-length
protein (34). Using expression vectors carrying GFP fused in frame with
either the full-length mouse dioxin receptor or the dioxin receptor
deletion mutant DR
LBD, we examined the effect of deletion of the
minimal LBD on intracellular localization of the dioxin receptor in
living cells. In control experiments, transient transfection of CHO
cells with the parental GFP construct alone revealed a uniform
distribution of fluorescence throughout the cell that was unaffected by
the presence of ligand (Fig. 1B). Transient expression of
the GFP-dioxin receptor fusion construct resulted in a similar
distribution as the parental GFP vector alone in untreated cells. As
expected, upon exposure to ligand, fluorescence rapidly accumulated in
the nuclear compartment of the cell (Fig. 1B) (34-36). In
contrast, however, expression of the GFP-DR
LBD fusion construct
showed constitutive nuclear localization in CHO cells even in the
absence of ligand (Fig. 1B). Thus, deletion of the minimal
LBD was sufficient to unmask the potent constitutive NLS activity
contained within the remaining structure of the receptor. Furthermore,
expression of a GFP fusion construct containing the minimal LBD of the
dioxin receptor encompassing amino acids 230-421 resulted in
constitutive cytoplasmic fluorescence that was unaffected by the
addition of ligand (Fig. 1B). Taken together, the results
indicate that the region encompassing the C-terminal portion of the PAS
domain harbors a structure(s) capable of repressing nuclear import of
the receptor. Since this region directly coincides with the core LBD of
the receptor, the results are consistent with a model whereby, in the
context of the full-length receptor, the ligand-binding domain is
capable of mediating conditional repression on a distant NLS.
To determine whether the nuclear localized, LBD-deficient mutant of the
dioxin receptor was transcriptionally active, we next analyzed reporter
gene activity by cotransfection with an XRE-driven luciferase reporter
gene in CHO cells (Fig. 1C). In control experiments, coexpression of the wild-type dioxin receptor together with Arnt resulted in dioxin-dependent activation of reporter gene
activity. To our surprise, however, coexpression of Arnt together with
the dioxin receptor deletion mutant DR
LBD failed to stimulate
reporter gene activity in the presence or absence of dioxin. Thus,
whereas deletion of the minimal ligand/hsp90-binding region of the
dioxin receptor was sufficient to unmask or derepress the constitutive NLS activity in the bHLH domain of the receptor, the resulting nuclear
localized protein failed to function as a ligand-independent transcriptional activator.
DR
LBD Is Impaired in Its Ability to Interact with Arnt and Fails
to Recognize the XRE Sequence Motif--
The C terminus of the dioxin
receptor harbors potent transactivation domains that, when attached to
a heterologous DNA-binding domain, can function autonomously,
displaying constitutive transcriptional activity (26, 33, 37). In the
natural structural context of the intact receptor, however,
transcriptional activity requires the presence of
ligand, suggesting an additional role for the LBD in regulation of the
distant transactivation function (26). Consequently, we wanted to
determine whether deletion of the minimal LBD in DR
LBD had been
sufficient to derepress the potent transcriptional activity inherent in
the C terminus of the receptor. To this end, we constructed a fusion
protein in which we replaced the N-terminal bHLH motif of DR
LBD with
the glucocorticoid receptor zinc finger DNA-binding domain
(GRDBD/DR
LBD). Whereas a reference chimeric receptor, GRDBD/DR (26),
containing an intact LBD showed strictly ligand-dependent
stimulation of a glucocorticoid response element-driven reporter gene
construct in CHO cells, the minimal LBD deletion chimera GRDBD/DR
LBD
displayed constitutive transcriptional activity that was unaffected by
the presence of ligand (Fig.
2A).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 2.
Deletion of the minimal LBD of the dioxin
receptor derepresses the potent C-terminal transactivation function of
the receptor and renders it independent of regulation by hsp90.
A, activities of the glucocorticoid receptor/dioxin
receptor chimeras in transient transfection assays in mammalian cells.
CHO cells were transiently transfected with the glucocorticoid response
element (GRE)-driven reporter gene construct
p(GRE)2T105LUC together with either GRDBD or the
GRDBD/dioxin receptor expression vectors as indicated. Following
transfection, cells were treated with either 10 nM TCDD
(black bars) or vehicle alone (0.1% Me2SO;
shaded bars). The control lanes (CTRL) represent
activity from the reporter alone and empty expression vector. Data are
from one experiment performed in duplicate and are representative of
three independent experiments. B, activities of the
GRDBD/dioxin receptor chimeras in yeast cells under conditions of
wild-type versus low levels of hsp90 expression. GRDBD and
the indicated GRDBD/mouse dioxin receptor chimeras were expressed in
yeast together with the reporter gene pUC SS26X under conditions of
normal (galactose; GAL) or low (glucose; GLU)
hsp90 expression levels in the presence (black bars) or
absence (shaded bars) of 10 µM
indolo[3,2-b]carbazole and assayed for
-galactosidase activity. Data are from one experiment performed in
duplicate and are representative of three independent experiments.
TK, thymidine kinase; CYC1, cytochrome
c1 promoters, respectively.
|
|
A number of biochemical experiments suggest that hsp90 regulates dioxin
receptor function by folding the receptor in a high affinity ligand
binding conformation (21). This model is strongly supported by yeast
(Saccharomyces cerevisiae) genetic experiments that
demonstrated that down-regulation of hsp90 expression levels results in
a ligand-non-responsive form of the receptor (20, 22). Importantly,
consistent with the deletion of the hsp90-binding region overlapping
with the ligand binding function of the dioxin receptor, the
transcriptional activity of the chimeric GRDBD/DR
LBD protein was
unaffected by changes in the level of hsp90 in yeast cells (Fig.
2B). Taken together, our results indicate that deletion of
the minimal domain harboring both the ligand- and hsp90-binding activities of the receptor efficiently derepresses the potent constitutive C-terminal transactivation function in DR
LBD and renders the transactivation function of the dioxin receptor independent of regulation by hsp90.
Given the inability of DR
LBD to function on an XRE-driven reporter
gene, we next examined whether the protein was deficient in its ability
to dimerize with Arnt or to bind DNA. To this end, we expressed the
wild-type dioxin receptor, DR
LBD, and Arnt by in vitro
translation in rabbit reticulocyte lysate. In control experiments, we
monitored wild-type dioxin receptor/Arnt dimerization activity by
incubating the [35S]methionine-labeled dioxin receptor
with an equal concentration of unlabeled Arnt in the presence or
absence of ligand, followed by immunoprecipitation using polyclonal
anti-Arnt antibodies. As expected, we observed
ligand-dependent interaction between the wild-type receptor
and Arnt (Fig. 3B, compare
lanes 2 and 3). In contrast, however, DR
LBD
failed to form a stable complex with Arnt in the presence or absence of
ligand since only low levels of nonspecific interaction were
demonstrated by the co-immunoprecipitation assay (Fig. 3B,
compare lanes 5 and 6). In excellent agreement with its impaired ability to interact with Arnt, DR
LBD failed to
bind the XRE sequence motif in gel mobility shift experiments (Fig.
3C). In conclusion, these results suggest that deletion of
the minimal LBD of the dioxin receptor strongly impairs the ability of
the receptor to recruit Arnt and thus form a DNA-binding complex,
possibly due to induction of conformational changes within the deletion
mutant.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 3.
DR LBD is impaired
in its ability to interact with Arnt and fails to recognize the XRE
sequence motif. A, shown are the results from the
analysis of the in vitro translated,
[35S]methionine-labeled wild-type dioxin receptor or the
dioxin receptor deletion mutant DR LBD. The positions of protein mass
markers are shown on the left. B, the deletion of the
minimal LBD of the dioxin receptor abrogated dimerization activity with
Arnt. Equal concentrations of the in vitro translated,
[35S]methionine-labeled dioxin receptor or DR LBD were
incubated with unlabeled Arnt in the presence (lanes 1,
2, 4, and 5) or absence (lanes
3 and 6) of 10 nM TCDD as indicated.
Co-immunoprecipitation was carried out with Arnt-specific antiserum
(S; lanes 2, 3, 5, and
6) or preimmune control serum (C; lanes
1 and 4). The resulting co-immunoprecipitated products
were visualized by SDS-PAGE and fluorography. C, in
vitro translated, unlabeled Arnt (lane 1), the dioxin
receptor (lane 2), the dioxin receptor deletion mutant
DR LBD (lanes 5 and 6), or mixtures of Arnt and
the dioxin receptor (lanes 3 and 4) or DR LBD
(lanes 7 and 8) were incubated with 10 nM TCDD or vehicle alone (0.1% Me2SO) for
2 h at 25 °C. DNA-binding activity was assessed by a gel
mobility shift assay using a 32P-labeled XRE
oligonucleotide probe. The positions of free probe (Free)
and the dioxin receptor-Arnt complex (DR/Arnt) are
indicated.
|
|
Definition of a Dioxin Receptor Deletion Mutant That
Shows Both Constitutive Dimerization Activity with Arnt and
Constitutive Interaction with the XRE Sequence Motif--
In addition
to harboring the minimal ligand- and hsp90-binding activities, the PAS
domain of the dioxin receptor has also been shown to mediate a number
of additional receptor activities. We have previously demonstrated that
the PAS domain of the dioxin receptor can function as a dimerization
interface independently of the bHLH domain in a hybrid-protein
interaction assay in mammalian cells (15). Furthermore, the C-terminal
half of the PAS domain located between amino acids 230 and 421 and
containing the minimal LBD spanning the PAS B motif has been shown to
be essential for the PAS-mediated interaction with Arnt (15). We
therefore examined the dimerization and DNA-binding activities of the
dioxin receptor deletion mutant DR
PASB, lacking the minimal PAS B
motif encompassed by amino acids 288-421, but maintaining the
N-terminal half of the LBD including the PAS A motif (Fig.
4A). Using in vitro
translated proteins together with the Arnt co-immunoprecipitation
assay, we first tested the ability of DR
PASB to dimerize in
vitro with Arnt. In contrast to the wild-type dioxin receptor,
which displayed ligand-dependent interaction with Arnt
(Fig. 4C, lanes 1 and 2) the minimal
PAS B deletion mutant (DR
PASB) showed constitutive dimerization
activity that was unaffected by the presence of ligand (lanes
3 and 4). Moreover, this mutant displayed far more
potent dimerization activity than the ligand-induced wild-type receptor (Fig. 4C, compare lanes 2-4). In gel mobility
shift experiments, DR
PASB bound the XRE motif together with Arnt
independently of the presence of ligand (Fig. 4D, compare
lanes 2 and 3). These results demonstrate that
additional sequences N-terminal of the minimal PAS B motif
incorporating the N-terminal half of the LBD are sufficient to
reconstitute dimerization and DNA-binding activity between the dioxin
receptor and Arnt. Since, in contrast to the wild-type dioxin receptor,
DR
PASB was able to bind Arnt in a ligand-independent manner, the
results also suggest that deletion of the minimal PAS B motif may be
sufficient to generate a conformational change in the bHLH domain of
the receptor to form a surface competent of interacting with Arnt
independently of ligand binding.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 4.
DR PASB shows both
constitutive dimerization activity with Arnt and constitutive
interaction with the XRE sequence motif. A, shown is a
schematic representation of the full-length mouse dioxin receptor
(mDR) and the dioxin receptor deletion mutant lacking the
C-terminal half of the minimal LBD (termed DR PASB). B,
shown are the results from the analysis of the in vitro
translated, [35S]methionine-labeled wild-type dioxin
receptor or the dioxin receptor deletion mutant DR PASB. The
positions of protein mass markers are shown on the left. C,
equal concentrations of the in vitro translated,
[35S]methionine dioxin receptor or DR PASB were
incubated with an equal concentration of unlabeled Arnt in the presence
or absence of 10 nM TCDD as indicated.
Co-immunoprecipitation was carried out with Arnt-specific antiserum,
and the resulting co-immunoprecipitated products were visualized by
SDS-PAGE and fluorography. D, in vitro
translated, unlabeled DR PASB (lane 1) or DR PASB
together with an equal concentration of unlabeled Arnt (lanes
2-6) was incubated for 2 h at 25 °C in the absence
(lanes 1, 2, and 4-6) or presence
(lane 3) of specific ligand. DNA-binding activity was
assessed by a gel mobility shift assay using a 32P-labeled
XRE probe. Specificity of DNA-binding complexes was analyzed by
incubation with receptor-specific ( DR; lane
4), Arnt-specific ( Arnt; lane 5), or
preimmune (P.I.S.; lane 6) serum. The positions
of free probe (Free), the dioxin receptor deletion
mutant-Arnt complex (DR PASB/Arnt), and a supershifted
complex (SS) are indicated.
|
|
Potent Constitutive Functional Activity of the Dioxin Receptor
Deletion Mutant Lacking the Minimal PAS B Motif--
We next examined
the functional activity of DR
PASB together with Arnt in transient
transfection assays using the XRE-driven luciferase reporter gene
construct. Although DR
PASB contained an N-terminal portion of the
ligand/hsp90-binding domain, in vitro translated DR
PASB
was unable to bind ligand in vitro (Fig.
5A). In addition, DR
PASB
maintained the ability to transactivate in a ligand- and
hsp90-independent manner as a GRDBD chimera in yeast cells (Fig.
5B), indicating that extension of the PAS domain to incorporate the N-terminal half of the minimal LBD did not impair the
functional activity of the C-terminal transactivation domain. Moreover,
it did not repress the ability of a GFP-DR
PASB fusion protein to
localize constitutively to the nucleus (Fig. 5C) (36).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 5.
Characterization of the dioxin receptor
deletion mutant DR PASB. A,
shown is ligand-binding activity. Unprogrammed rabbit reticulocyte
lysate (control (CTRL)) or lysate containing equal
concentrations of the in vitro translated, full-length
dioxin receptor or the dioxin receptor deletion mutant DR PASB was
incubated with 1 nM [3H]TCDD for 90 min at
25 °C and then adsorbed to hydroxylapatite for 30 min at 4 °C.
After extensive washing, bound [3H]TCDD was determined by
scintillation counting. Specificity of the binding reaction was
assessed by competition with a 150-fold molar excess of unlabeled
ligand (tetrachlorodibenzofuran) as indicated. B, the
activity of the GRDBD/DR PASB chimera was unaffected under conditions
of low hsp90 expression in yeast cells. GRDBD and the GRDBD/DR PASB
chimera were expressed in yeast under conditions of normal (galactose;
GAL) or low (glucose; GLU) hsp90 expression
levels in the presence (black bars) or absence (shaded
bars) of 10 µM indolo[3,2-b]carbazole
and assayed for -galactosidase activity. Data represent average
values from two samples assayed in a given experiment. C,
CHO cells grown on glass coverslips were transfected with 1 µg of
expression plasmid for GFP-DR PASB. Twenty-four hours after
transfection, the cells were treated with 10 nM TCDD or
vehicle (Me2SO) for 2 h as indicated. The cells were
then washed with PBS and fixed with 4% paraformaldehyde. The
localization of GFP-DR PASB fusion protein was observed as described
in the legend to Fig. 1B, and representative images are
shown. The experiments were repeated at least three times with similar
results. Original magnification was ×400.
|
|
In contrast to the wild-type dioxin receptor, DR
PASB strongly
stimulated XRE-driven reporter gene activity upon coexpression with
Arnt in CHO cells in the absence of ligand (Fig.
6A). Thus, in the natural
structural context of the intact receptor, the PAS B motif is the
critical determinant to maintain the receptor in a transcriptionally
inactive state. Furthermore, the observed reporter gene activity was
unaffected by the presence of ligand, demonstrating that this dioxin
receptor deletion mutant functioned as a constitutively active
regulatory protein. To our surprise, however, the constitutive activity
of DR
PASB was found to be more potent than that produced by the
wild-type receptor exposed to a maximally inducing dose of
dioxin (Fig. 6A). In these experiments, the wild-type dioxin
receptor and the dioxin receptor deletion mutant were expressed at
similar levels (Fig. 6B). Potent transactivation was
observed in a number of different cell lines, including human cervical
adenocarcinoma HeLa and mouse adrenal Y1 cells (Fig. 6C)
(data not shown).

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 6.
Constitutive activity of
DR PASB in mammalian cells. A
and C, CHO and HeLa cells, respectively, were transiently
transfected with the XRE-driven luciferase reporter gene pTX.DIR
together with the either wild-type dioxin receptor or the dioxin
receptor deletion mutant DR PASB and Arnt. Following transfection,
cells were treated with 10 nM TCDD (black bars)
or vehicle alone (0.1% Me2SO; shaded bars) as
indicated. Data are presented as luciferase activity relative to cells
transfected with empty expression vector and reporter gene alone
(control (CTRL)) in the absence of ligand. Values represent
the mean ± S.E. of three independent experiments performed in
duplicate. B, shown is the detection of the wild-type dioxin
receptor or the dioxin receptor deletion mutant DR PASB following
transient expression in CHO cells. Whole cell extracts (30 µg of
protein) were separated by 7.5% SDS-PAGE and transferred to
nitrocellulose membrane, and the relative expression levels of the
full-length dioxin receptor (lane 2) and DR PASB
(lane 3) were determined by immunodetection with monoclonal
anti-FLAG antibody, followed by chemiluminescence. Lane 1 represents whole cell extracts from untransfected cells. The positions
of protein mass markers are shown on the left.
|
|
 |
DISCUSSION |
Transcription factors are generally acknowledged to have a modular
structure. In the case of the dioxin receptor, the receptor is composed
of a number of domains that harbor distinct separable functions,
including N-terminal DNA-binding and dimerization domains and a
C-terminal transactivation domain. Ligand binding by the dioxin
receptor is an independent property of the centrally located LBD
encompassing amino acids 230-421 and spanning the C-terminal half of
the PAS domain. Moreover, this minimal LBD of the dioxin receptor has
been shown to be transferable, retaining its activity when attached to
other proteins, supporting the view that receptor LBDs are independent
entities containing all the information necessary for ligand binding
(19). In addition to being a critical determinant of ligand-binding
activity, the LBD of the dioxin receptor has also been postulated to
function in the repression of receptor function in the absence of
ligand (19). Similarly, in the absence of specific agonist, the LBD of
the glucocorticoid receptor functions in the repression of a number of
receptor activities, including nuclear localization, dimerization, DNA
binding, and transactivation. Exposure to agonist ligand induces
nuclear import and results in derepression of receptor function (38,
39). Thus, within the normal context of the intact receptor, the LBD
specifies a reversible inactivation function that, in the absence of
ligand, inhibits other receptor activities. In this study, we have
demonstrated that deletion of the minimal LBD of the dioxin receptor
results in a protein that is constitutively localized to the nucleus. In striking contrast to steroid receptors, however, this nuclear localized, LBD-deficient mutant of the receptor was functionally inert
in reporter gene assays in the presence and absence of ligand. Further
analysis revealed that, although the C-terminal transactivation function had been efficiently derepressed, this receptor deletion mutant had lost the ability to dimerize with Arnt, thus rendering it
incapable of forming an active DNA-binding complex. Inclusion of the
N-terminal amino acids of the minimal delineated LBD to the border of
the PAS B motif reconstituted dimerization and DNA-binding activity
with Arnt. Moreover, the presence of the N-terminal half of the LBD did
not impair either the N-terminal NLS activity or the functional
activity of the C-terminal transactivation domain of the receptor,
indicating that this region is not required for repression of these
receptor activities. Furthermore, the receptor was now converted into a
constitutive transcriptional activator. Thus, whereas the entire LBD of
the glucocorticoid receptor appears to regulate all of these receptor
activities, our results suggest that the C-terminal half of the minimal
delineated LBD of the dioxin receptor incorporating the PAS B motif is
both sufficient and required to maintain the receptor in a
transcriptionally inactive state in the absence of ligand.
Previous studies have clearly defined the minimal sequence of the LBD
of the dioxin receptor with wild-type ligand binding affinity as
extending from amino acids 230 to 421 (21). Moreover, this region of
the receptor has also been shown to modulate interaction with the
molecular chaperone hsp90, consistent with its role in the folding of a
high affinity ligand binding conformation of the receptor (20-22). In
this study, we have observed that deletion of the C-terminal half of
the LBD incorporating the PAS B motif abolished ligand binding,
revealing the critical nature of the residues between amino acids 288 and 421 for ligand-binding activity. Interestingly, this dioxin
receptor deletion mutant had also lost the ability to associate with
hsp90 in vitro, suggesting that the region spanning the
C-terminal half of the minimal LBD incorporating the PAS B motif is the
target for regulation by hsp90. In support of this model, the activity
of this dioxin receptor deletion mutant was unaffected by reduced
levels of hsp90 in the yeast model system. We propose therefore that,
in addition to modulating repression of receptor function in the
absence of ligand, this region of the receptor may also be required for
the folding of the entire delineated LBD to give the native tertiary
structure that is optimal for high affinity ligand binding possibly by
association with hsp90.
In summary, we have identified the domain of the dioxin receptor that
determines repression of receptor function to be the C-terminal
134 amino acids of the LBD. In addition, our results indicate that this
region of the receptor is the target for regulation by hsp90.
Furthermore, deletion of this domain converts the receptor into a
constitutive transcriptional activator. In conclusion, the
constitutively active dioxin receptor may provide an important mechanistic tool to investigate receptor-mediated regulatory pathways in closer detail.
 |
ACKNOWLEDGEMENT |
We thank Amina Ossoinak for excellent
technical assistance.
 |
FOOTNOTES |
*
This work was supported by grants from the Swedish Cancer
Society, the European Union, and the NOVARTIS Foundation (Japan) for the Promotion of Science.The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.:
46-8-728-7330; Fax: 46-8-34-88-19; E-mail:
lorenz.poellinger@cmb.ki.se.
Published, JBC Papers in Press, September 10, 2001, DOI 10.1074/jbc.M105607200
 |
ABBREVIATIONS |
The abbreviations used are:
TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin;
hsp90, 90-kDa heat
shock protein;
bHLH, basic helix-loop-helix;
LBD, ligand-binding
domain;
XRE, xenobiotic response element;
DR, dioxin receptor;
GRDBD, glucocorticoid receptor zinc finger DNA-binding domain;
PCR, polymerase
chain reaction;
GFP, green fluorescent protein;
CHO, Chinese hamster
ovary;
PBS, phosphate-buffered saline;
PAGE, polyacrylamide gel
electrophoresis;
NLS, nuclear localization signal.
 |
REFERENCES |
| 1.
|
Gu, Y. Z.,
Hogenesch, J. B.,
and Bradfield, C. A.
(2000)
Annu. Rev. Pharmacol. Toxicol.
40,
519-561[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Fernandez-Salguero, P.,
Pineau, T.,
Hilbert, D. M.,
McPhail, T.,
Lee, S. S.,
Kimura, S.,
Nebert, D. W.,
Rudikoff, S.,
Ward, J. M.,
and Gonzalez, F. J.
(1995)
Science
268,
722-726[Abstract/Free Full Text]
|
| 3.
|
Schmidt, J. V.,
Su, G. H.,
Reddy, J. K.,
Simon, M. C.,
and Bradfield, C. A.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
6731-6736[Abstract/Free Full Text]
|
| 4.
|
Mimura, J.,
Yamashita, K.,
Nakamura, K.,
Morita, M.,
Takagi, T. N.,
Nakao, K.,
Ema, M.,
Sogawa, K.,
Yasuda, M.,
Katsuki, M.,
and Fujii-Kuriyama, Y.
(1997)
Genes Cells
2,
645-654[Abstract]
|
| 5.
|
Lahvis, G. P.,
Lindell, S. L.,
Thomas, R. S.,
McCuskey, R. S.,
Murphy, C.,
Glover, E.,
Bentz, M.,
Southard, J.,
and Bradfield, C. A.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
10442-10447[Abstract/Free Full Text]
|
| 6.
|
Perdew, G. H.
(1992)
Biochem. Biophys. Res. Commun.
182,
55-62[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Chen, H. S.,
and Perdew, G. H.
(1994)
J. Biol. Chem.
269,
27554-27558[Abstract/Free Full Text]
|
| 8.
|
Carver, L. A.,
and Bradfield, C. A.
(1997)
J. Biol. Chem.
272,
11452-11456[Abstract/Free Full Text]
|
| 9.
|
Ma, Q.,
and Whitlock, J. P.
(1997)
J. Biol. Chem.
272,
8878-8884[Abstract/Free Full Text]
|
| 10.
|
Meyer, B. K.,
Pray-Grant, M. G.,
Vanden Heuvel, J. P.,
and Perdew, G. H.
(1998)
Mol. Cell. Biol.
18,
978-988[Abstract/Free Full Text]
|
| 11.
|
Kazlauskas, A.,
Poellinger, L.,
and Pongratz, I.
(1999)
J. Biol. Chem.
274,
13519-13524[Abstract/Free Full Text]
|
| 12.
|
Crews, S. T.
(1998)
Genes Dev.
12,
607-620[Free Full Text]
|
| 13.
|
Taylor, B. L.,
and Zhulin, I. B.
(1999)
Microbiol. Mol. Biol. Rev.
63,
479-506[Abstract/Free Full Text]
|
| 14.
|
Huang, Z. J.,
Edery, I.,
and Rosbash, M.
(1993)
Nature
364,
259-262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Lindebro, M. C.,
Poellinger, L.,
and Whitelaw, M. L.
(1995)
EMBO J.
14,
3528-3539[Medline]
[Order article via Infotrieve]
|
| 16.
|
Pongratz, I.,
Antonsson, C.,
Whitelaw, M. L.,
and Poellinger, L.
(1998)
Mol. Cell. Biol.
18,
4079-4088[Abstract/Free Full Text]
|
| 17.
|
Zelzer, E.,
Wappner, P.,
and Shilo, B. Z.
(1997)
Genes Dev.
11,
2079-2089[Abstract/Free Full Text]
|
| 18.
|
Burbach, K. M.,
Poland, A.,
and Bradfield, C. A.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
8185-8189[Abstract/Free Full Text]
|
| 19.
|
Whitelaw, M. L.,
Gottlicher, M.,
Gustafsson, J. Å.,
and Poellinger, L.
(1993)
EMBO J.
12,
4169-4179[Medline]
[Order article via Infotrieve]
|
| 20.
|
Carver, L. A.,
Jackiw, V.,
and Bradfield, C. A.
(1994)
J. Biol. Chem.
269,
30109-30112[Abstract/Free Full Text]
|
| 21.
|
Coumailleau, P.,
Poellinger, L.,
Gustafsson, J. Å.,
and Whitelaw, M. L.
(1995)
J. Biol. Chem.
270,
25291-25300[Abstract/Free Full Text]
|
| 22.
|
Whitelaw, M. L.,
McGuire, J.,
Picard, D.,
Gustafsson, J. Å.,
and Poellinger, L.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
4437-4441[Abstract/Free Full Text]
|
| 23.
|
McGuire, J.,
Whitelaw, M. L.,
Pongratz, I.,
Gustafsson, J. Å.,
and Poellinger, L.
(1994)
Mol. Cell. Biol.
14,
2438-2446[Abstract/Free Full Text]
|
| 24.
|
Mason, G. G.,
Witte, A. M.,
Whitelaw, M. L.,
Antonsson, C.,
McGuire, J.,
Wilhelmsson, A.,
Poellinger, L.,
and Gustafsson, J. Å.
(1994)
J. Biol. Chem.
269,
4438-4449[Abstract/Free Full Text]
|
| 25.
|
Kallio, P. J.,
Okamoto, K.,
O'Brien, S.,
Carrero, P.,
Makino, Y.,
Tanaka, H.,
and Poellinger, L.
(1998)
EMBO J.
17,
6573-6586[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Whitelaw, M. L.,
Gustafsson, J. Å.,
and Poellinger, L.
(1994)
Mol. Cell. Biol.
14,
8343-8355[Abstract/Free Full Text]
|
| 27.
|
Berghard, A.,
Gradin, K.,
Pongratz, I.,
Whitelaw, M.,
and Poellinger, L.
(1993)
Mol. Cell. Biol.
13,
677-689[Abstract/Free Full Text]
|
| 28.
|
Gradin, K.,
Whitelaw, M. L.,
Toftgård, R.,
Poellinger, L.,
and Berghard, A.
(1994)
J. Biol. Chem.
269,
23800-23807[Abstract/Free Full Text]
|
| 29.
|
Picard, D.,
Khursheed, B.,
Garabedian, M. J.,
Fortin, M. G.,
Lindquist, S.,
and Yamamoto, K. R.
(1990)
Nature
348,
166-168[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Gietz, D.,
St. Jean, A.,
Woods, R. A.,
and Schiestl, R. H.
(1992)
Nucleic Acids Res.
20,
1425[Free Full Text]
|
| 31.
|
Antonsson, C.,
Whitelaw, M. L.,
McGuire, J.,
Gustafsson, J. Å.,
and Poellinger, L.
(1995)
Mol. Cell. Biol.
15,
756-765[Abstract]
|
| 32.
|
Cuthill, S.,
Wilhelmsson, A.,
and Poellinger, L.
(1991)
Mol. Cell. Biol.
11,
401-411[Abstract/Free Full Text]
|
| 33.
|
Ma, Q.,
Dong, L.,
and Whitlock, J. P.
(1995)
J. Biol. Chem.
270,
12697-12703[Abstract/Free Full Text]
|
| 34.
|
Ikuta, T.,
Eguchi, H.,
Tachibana, T.,
Yoneda, Y.,
and Kawajiri, K.
(1998)
J. Biol. Chem.
273,
2895-2904[Abstract/Free Full Text]
|
| 35.
|
Kazlauskas, A.,
Poellinger, L.,
and Pongratz, I.
(2000)
J. Biol. Chem.
275,
41317-41324[Abstract/Free Full Text]
|
| 36.
|
Kazlauskas, A.,
Sundström, S.,
Poellinger, L.,
and Pongratz, I.
(2001)
Mol. Cell. Biol.
21,
2594-2607[Abstract/Free Full Text]
|
| 37.
|
Jain, S.,
Dolwick, K. M.,
Schmidt, J. V.,
and Bradfield, C. A.
(1994)
J. Biol. Chem.
269,
31518-31524[Abstract/Free Full Text]
|
| 38.
|
Yamamoto, K. R.,
Godowski, P. J.,
and Picard, D.
(1988)
Cold Spring Harbor Symp. Quant. Biol.
53,
803-811
|
| 39.
|
Mangelsdorf, D. J.,
Thummel, C.,
Beato, M.,
Herrlich, P.,
Schutz, G.,
Umesono, K.,
Blumberg, B.,
Kastner, P.,
Mark, M.,
Chambon, P.,
and Evans, R. M.
(1995)
Cell
83,
835-839[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. Dabir, T. E. Marinic, I. Krukovets, and O. I. Stenina
Aryl Hydrocarbon Receptor Is Activated by Glucose and Regulates the Thrombospondin-1 Gene Promoter in Endothelial Cells
Circ. Res.,
June 20, 2008;
102(12):
1558 - 1565.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. R. Evans, S. I. Karchner, L. L. Allan, R. S. Pollenz, R. L. Tanguay, M. J. Jenny, D. H. Sherr, and M. E. Hahn
Repression of Aryl Hydrocarbon Receptor (AHR) Signaling by AHR Repressor: Role of DNA Binding and Competition for AHR Nuclear Translocator
Mol. Pharmaco |